icad inc. (NASDAQ:ICAD) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ICAD to report 3Q20 loss of $ 0.11 per share.
For the full year, analysts anticipate top line of $ 26.31 million, while looking forward to loss of $ 0.47 per share bottom line.
Previous Quarter Performance
icad inc. unwinded loss for the second quarter of $ 0.12 per share, from the revenue of $ 5.57 million. The quarterly revenues contracted 24.01 percent compared with the same quarter last year. Wall street analysts are predicting, ICAD to report 2Q20 loss of $ 0.22 per share from revenue of $ 4.23 million. The bottom line results beat street analysts by $ 0.1 or 45.45 percent, at the same time, top line results outshined analysts by $ 1.34 million or 31.68 percent.
Stock Performance
Shares of icad inc. traded low $ -0.39 or -3.83 percent on Wednesday, reaching $ 9.79 with volume of 124.40 thousand shares. icad inc. has traded high as $ 10.44 and has cracked $ 9.59 on the downward trend
The closing price of $ 9.79, representing a 72.25 % increase from the 52 week low of $ 5.91 and a 33.51 % decrease over the 52 week high of $ 15.31.
The company has a market capital of $ 224.20 million and is part of the Technology sector and Health Information Services industry.
Conference Call
icad inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.icadmed.com
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy.
